What is the current valuation of the biomarker test market in the GCC region?

The market valuation reached $704.7 Million in 2024. Read More

What is the projected market size for the biomarker test market by 2035?

The market is expected to grow to $1126.0 Million by 2035. Read More

What is the expected CAGR for the biomarker test market from 2025 to 2035?

The anticipated CAGR during the forecast period is 4.35%. Read More

Which application segment holds the highest valuation in the biomarker test market?

The metabolic diseases segment was valued at $254.7 Million in 2024. Read More

What are the projected values for oncology in the biomarker test market?

Oncology is projected to grow from $150.0 Million to $240.0 Million by 2035. Read More

Which type of test is expected to have the highest valuation in the market?

Microbiome tests were valued at $244.7 Million in 2024 and are expected to grow significantly. Read More

What technology segment is projected to see the most growth in the biomarker test market?

Next-generation sequencing is expected to grow from $234.7 Million to $376.0 Million by 2035. Read More

Which end-use segment had the highest valuation in 2024?

Hospitals had the highest valuation at $200.0 Million in 2024. Read More

Who are the key players in the biomarker test market?

Key players include Roche Diagnostics, Abbott Laboratories, and Thermo Fisher Scientific. Read More

What is the projected growth for the cardiovascular segment in the biomarker test market?

The cardiovascular segment is expected to grow from $120.0 Million to $190.0 Million by 2035. Read More

GCC Biomarker Test Market

GCC Biomarker Test Market Research Report By Application (Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Diseases), By Type of Test (Genetic Tests, Proteomic Tests, Metabolomic Tests, Microbiomic Tests), By Technology (Polymerase Chain Reaction, Mass Spectrometry, Immunoassays, Next-Generation Sequencing) and By End Use (Hospitals, Clinical Laboratories, Research Institutions, Pharmaceutical Companies) -Forecast to 2035

Forecast Period

2025 - 2035

CAGR

4.35%

2024 Market Size

$ 704.7 Million

2035 Market Size

$ 1,126 Million

Healthcare ● Updated August 2026 Report ID: MRFR/HC/54580-HCR | Pages: 200 | Author: Satyendra Maurya, Rahul Gotadki

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Application (USD Million)
  1. 4.1.1 Oncology
  2. 4.1.2 Cardiovascular
  3. 4.1.3 Neurology
  4. 4.1.4 Infectious Diseases
  5. 4.1.5 Metabolic Diseases
2. 4.2 Healthcare, BY Type of Test (USD Million)
  1. 4.2.1 Genetic Tests
  2. 4.2.2 Proteomic Tests
  3. 4.2.3 Metabolomic Tests
  4. 4.2.4 Microbiome Tests
3. 4.3 Healthcare, BY Technology (USD Million)
  1. 4.3.1 Polymerase Chain Reaction
  2. 4.3.2 Mass Spectrometry
  3. 4.3.3 Immunoassays
  4. 4.3.4 Next-Generation Sequencing
4. 4.4 Healthcare, BY End-Use (USD Million)
  1. 4.4.1 Hospitals
  2. 4.4.2 Clinical Laboratories
  3. 4.4.3 Research Institutions
  4. 4.4.4 Pharmaceutical Companies
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Roche Diagnostics (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Abbott Laboratories (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Thermo Fisher Scientific (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Agilent Technologies (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Bio-Rad Laboratories (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Qiagen (DE)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Illumina (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 PerkinElmer (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Merck KGaA (DE)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 GCC MARKET ANALYSIS BY APPLICATION
3. 6.3 GCC MARKET ANALYSIS BY TYPE OF TEST
4. 6.4 GCC MARKET ANALYSIS BY TECHNOLOGY
5. 6.5 GCC MARKET ANALYSIS BY END-USE
6. 6.6 KEY BUYING CRITERIA OF HEALTHCARE
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF HEALTHCARE
9. 6.9 DRIVERS IMPACT ANALYSIS: HEALTHCARE
10. 6.10 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
11. 6.11 SUPPLY / VALUE CHAIN: HEALTHCARE
12. 6.12 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
13. 6.13 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Million)
14. 6.14 HEALTHCARE, BY TYPE OF TEST, 2024 (% SHARE)
15. 6.15 HEALTHCARE, BY TYPE OF TEST, 2024 TO 2035 (USD Million)
16. 6.16 HEALTHCARE, BY TECHNOLOGY, 2024 (% SHARE)
17. 6.17 HEALTHCARE, BY TECHNOLOGY, 2024 TO 2035 (USD Million)
18. 6.18 HEALTHCARE, BY END-USE, 2024 (% SHARE)
19. 6.19 HEALTHCARE, BY END-USE, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 GCC MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.2.2 BY TYPE OF TEST, 2025-2035 (USD Million)
  3. 7.2.3 BY TECHNOLOGY, 2025-2035 (USD Million)
  4. 7.2.4 BY END-USE, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

GCC Biomarker Test Market Segmentation

GCC Biomarker Test Market By Application (USD Million, 2025-2035)

Oncology
Cardiovascular
Neurology
Infectious Diseases
Metabolic Diseases

GCC Biomarker Test Market By Type of Test (USD Million, 2025-2035)

Genetic Tests
Proteomic Tests
Metabolomic Tests
Microbiome Tests

GCC Biomarker Test Market By Technology (USD Million, 2025-2035)

Polymerase Chain Reaction
Mass Spectrometry
Immunoassays
Next-Generation Sequencing

GCC Biomarker Test Market By End-Use (USD Million, 2025-2035)

Hospitals
Clinical Laboratories
Research Institutions
GCC Biomarker Test Market Companies

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”